|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1998-3-18
|
|
pubmed:abstractText |
To evaluate the impact on the response rate in patients with advanced breast cancer (ABC) of the doubling of the dose intensity (DI) of epirubicin monotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:AndreopoulouEE,
pubmed-author:AthanassiadesAA,
pubmed-author:BafaloukosDD,
pubmed-author:BamiaCC,
pubmed-author:BriasoulisEE,
pubmed-author:FountzilasGG,
pubmed-author:GiannakakisTT,
pubmed-author:KalofonosHH,
pubmed-author:Kalogera-FountzilaAA,
pubmed-author:KosmidisPP,
pubmed-author:OnienaoumAA,
pubmed-author:PavlidisNN,
pubmed-author:PectasidesDD,
pubmed-author:SkarlosDD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1213-20
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9496386-Adult,
pubmed-meshheading:9496386-Aged,
pubmed-meshheading:9496386-Antibiotics, Antineoplastic,
pubmed-meshheading:9496386-Breast Neoplasms,
pubmed-meshheading:9496386-Disease-Free Survival,
pubmed-meshheading:9496386-Drug Administration Schedule,
pubmed-meshheading:9496386-Epirubicin,
pubmed-meshheading:9496386-Female,
pubmed-meshheading:9496386-Humans,
pubmed-meshheading:9496386-Middle Aged,
pubmed-meshheading:9496386-Survival Analysis,
pubmed-meshheading:9496386-Treatment Outcome
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study.
|
|
pubmed:affiliation |
'AHEPA' Hospital, Aristotle University of Thessaloniki, Greece.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
